ABOUT USOUR SCIENCEOUR TEAM
PARTNERING
INVESTMENTLATEST NEWSCAREERS
GET IN TOUCH
About Us
Our Science
Our Team
partnering
Business Development
Scientific Collaboration
Investment
Latest News
Careers
GET IN TOUCH
ABOUT USOUR SCIENCEOUR TEAM
PARTNERING
INVESTMENTLATEST NEWSCAREERS
GET IN TOUCH

Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

November 2024

Pilatus Biosciences Inc. Receives Orphan Drug Designation from FDA for PLT012 in Treatment of Liver and Intrahepatic Bile Duct Cancer

October 2024

Pilatus Biosciences Announces Preclinical Data of Anti-PD-L1/IL-10 Immunocytokine PLT011 at SITC 2023

March 2024

Pilatus Biosciences Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling Preclinical Proof of Concept Data on PLT012, Highlighting its Role in Reprogramming the Tumor Microenvironment against Cancer

October 2023

Pilatus Biosciences Announces Preclinical Data of First-in-class Anti-CD36 Antibody PLT012 at SITC 2023

Upcoming Events

September 16, 2025

-

September 17, 2025

Boston

LSX USA Congress, Boston

More Info

September 16, 2025

-

Boston

Citeline PharmaIgnite, Boston

More Info

September 30, 2025

-

Fujisawa, Kanagawa

Innovation Tiger, Japan

More Info

Unlocking Immune Potential with
Innovative Metabolic Reprogramming

Pilatus Biosciences

Pilatus Biosciences SA
Route de la Corniche 6
1066 Epalinges
Vaud - SWITZERLAND
Pilatus Biosciences Corp
17F-1, No. 508, Section 7,
Zhongxiao East Road,
Nangang District, 
Taipei City 115, Taiwan
info@pilatusbio.com

Links

AboutOur ScienceOur TeamBusiness
DevelopmentScientific
CollaborationLatest NewsCareers

© 2025 Pilatus Biosciences. All Rights Reserved.

Privacy Policy